Arbutus Biopharma Corporation
NASDAQ:ABUS
Overview | Financials
Company Name | Arbutus Biopharma Corporation |
Symbol | ABUS |
Currency | USD |
Price | 3.19 |
Market Cap | 604,479,480 |
Dividend Yield | 0% |
52-week-range | 2.21 - 4.72 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. William H. Collier |
Website | https://www.arbutusbio.com |
An error occurred while fetching data.
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD